Daniela D Rosa

Summary

Publications

  1. doi request reprint Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma
    Daniela D Rosa
    Department of Medicine, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Arch Gynecol Obstet 278:457-62. 2008
  2. pmc Association of adipokines and adhesion molecules with indicators of obesity in women undergoing mammography screening
    Caroline Isoppo de Souza
    Programa de Pós Graduação em Medicina Ciências Médicas, Universidade Federal do Rio Grande do Sul UFRGS, Rio Grande do Sul, Brasil
    Nutr Metab (Lond) 9:97. 2012
  3. doi request reprint Adjuvant platinum-based chemotherapy for early stage cervical cancer
    Daniela D Rosa
    OncologyUnit, HospitalMoinhos deVento, PortoAlegre, Brazil
    Cochrane Database Syst Rev 6:CD005342. 2012
  4. pmc Candidaemia and cancer: patients are not all the same
    Alessandro Comaru Pasqualotto
    Medical School, The University of Manchester, UK
    BMC Infect Dis 6:50. 2006
  5. ncbi request reprint Molecular-targeted therapies: lessons from years of clinical development
    Daniela D Rosa
    Medical Oncology Clinic, Jules Bordet Institute, and L Universite Libre de Bruxelles ULB, Brussels, Belgium
    Cancer Treat Rev 34:61-80. 2008
  6. ncbi request reprint The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma
    D D Rosa
    Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK
    Clin Oncol (R Coll Radiol) 19:125-8. 2007
  7. ncbi request reprint The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma
    D D Rosa
    Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester
    Eur J Surg Oncol 32:588-91. 2006
  8. ncbi request reprint The best guess approach to phase I trial design
    Daniela D Rosa
    Cancer Research United Kingdom, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom
    J Clin Oncol 24:206-8. 2006
  9. ncbi request reprint HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer
    E Azambuja
    Department of Medical Oncology and Translational Research Unit Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 19:223-32. 2008
  10. ncbi request reprint Antiangiogenic therapy for ovarian cancer
    Daniela D Rosa
    Cancer Research UK and University of Manchester, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Curr Opin Oncol 19:497-505. 2007

Collaborators

Detail Information

Publications17

  1. doi request reprint Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma
    Daniela D Rosa
    Department of Medicine, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Arch Gynecol Obstet 278:457-62. 2008
    ..We present data from heavily pretreated patients to whom the folinic acid, 5-fluorouracil and oxaliplatin (Folfox) regimen was administered. The objectives were to assess response rate and to evaluate the safety profile...
  2. pmc Association of adipokines and adhesion molecules with indicators of obesity in women undergoing mammography screening
    Caroline Isoppo de Souza
    Programa de Pós Graduação em Medicina Ciências Médicas, Universidade Federal do Rio Grande do Sul UFRGS, Rio Grande do Sul, Brasil
    Nutr Metab (Lond) 9:97. 2012
    ..abstract:..
  3. doi request reprint Adjuvant platinum-based chemotherapy for early stage cervical cancer
    Daniela D Rosa
    OncologyUnit, HospitalMoinhos deVento, PortoAlegre, Brazil
    Cochrane Database Syst Rev 6:CD005342. 2012
    ....
  4. pmc Candidaemia and cancer: patients are not all the same
    Alessandro Comaru Pasqualotto
    Medical School, The University of Manchester, UK
    BMC Infect Dis 6:50. 2006
    ..Most of the studies about invasive Candida infections in cancer patients have focused on haematological patients. The aim of this study was to provide information about risk factors for candidaemia in patients with solid tumours...
  5. ncbi request reprint Molecular-targeted therapies: lessons from years of clinical development
    Daniela D Rosa
    Medical Oncology Clinic, Jules Bordet Institute, and L Universite Libre de Bruxelles ULB, Brussels, Belgium
    Cancer Treat Rev 34:61-80. 2008
    ....
  6. ncbi request reprint The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma
    D D Rosa
    Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK
    Clin Oncol (R Coll Radiol) 19:125-8. 2007
    ..This work was designed to verify whether the neoadjuvant approach had an effect on survival in patients with advanced-stage ovarian cancer...
  7. ncbi request reprint The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma
    D D Rosa
    Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester
    Eur J Surg Oncol 32:588-91. 2006
    ..To study the effect of the interval between surgery and the start of chemotherapy in the treatment of patients with advanced ovarian cancer...
  8. ncbi request reprint The best guess approach to phase I trial design
    Daniela D Rosa
    Cancer Research United Kingdom, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom
    J Clin Oncol 24:206-8. 2006
  9. ncbi request reprint HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer
    E Azambuja
    Department of Medical Oncology and Translational Research Unit Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 19:223-32. 2008
    ..Prospective, randomized trials incorporating important biological hypotheses are either ongoing or just closed, and their results will hopefully help to shed more light on this issue...
  10. ncbi request reprint Antiangiogenic therapy for ovarian cancer
    Daniela D Rosa
    Cancer Research UK and University of Manchester, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
    Curr Opin Oncol 19:497-505. 2007
    ..To highlight the current antiangiogenic compounds being evaluated as single agents or in association with chemotherapy in the treatment of ovarian cancer, as well as the rationale for their development...
  11. ncbi request reprint Vascular endothelial growth factors and receptors in colorectal cancer: implications for anti-angiogenic therapy
    Sarah E Duff
    Department of Surgery, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom
    Eur J Cancer 42:112-7. 2006
    ..A component of the therapeutic benefit might be due to a direct anti-tumour effect as well as an anti-angiogenic effect...
  12. ncbi request reprint Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis
    Sin C Lau
    Cancer Research UK, Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK
    Curr Opin Mol Ther 7:493-501. 2005
    ..sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer...
  13. ncbi request reprint Current management of ovarian carcinosarcoma
    M S Mano
    Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    Int J Gynecol Cancer 17:316-24. 2007
    ..However, this procedure has been associated with higher rates of complication in OCS and should only be attempted by experienced (gynecological) surgeons in centers with expertise in the management of gynecological malignancies...
  14. ncbi request reprint OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy
    Daniela D Rosa
    J Clin Oncol 24:5176-7; author reply 5177. 2006
  15. ncbi request reprint Antibacterial prophylaxis in patients with cancer and neutropenia
    Alessandro C Pasqualotto
    N Engl J Med 354:90-4; author reply 90-4. 2006
  16. ncbi request reprint Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma
    Shirley Ralph
    Renal Research Laboratories, Manchester Institute of Nephrology and Transplantation, CMMC University Hospital Trust, Oxford Road, Manchester M13 9WL, UK
    Cancer Sci 98:844-9. 2007
    ..The CGC HSPE-1 haplotype associates with stage in ovarian cancer. This haplotype may affect splicing of the HSPE-1 gene, as in silico it alters the presence of a splicing motif...
  17. ncbi request reprint Multinational clinical trials in oncology and post-trial benefits for host countries: where do we stand?
    Max S Mano
    Institut Jules Bordet, Unité d Oncologie Médicale, Rue Héger Bordet 01, 1000 Brussels, Belgium
    Eur J Cancer 42:2675-7. 2006
    ..Upfront arrangements ensuring post-trial access to interventions that have been proven successful might be the best alternative to exclusion from the research...